Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1597070 | 1.00 | REN (0.49) | REN | |
| SCHEMBL1597075 | 1.00 | REN (0.49) | REN | |
| SCHEMBL6030113 | 1.00 | REN (0.49) | REN | |
| SCHEMBL1595427 | 0.89 | REN (0.49) | REN | |
| SCHEMBL427626 | 0.88 | REN (0.49) | REN | |
| SCHEMBL427625 | 0.88 | REN (0.49) | REN | |
| SCHEMBL427624 | 0.88 | REN (0.49) | REN | |
| SCHEMBL1595422 | 0.86 | REN (0.49) | REN | |
| SCHEMBL1595426 | 0.86 | REN (0.49) | REN | |
| SCHEMBL4640310 | 0.83 | REN (0.45) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689702-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-7919529-B2 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | NOVARTIS AG (CH) | 2011-04-05 | — | — | US | disclosed |
| EP-2266951-A1 | Organic compounds | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-7851642-B2 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compound | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20090253701-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253703-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253701-A1 | ORGANIC COMPOUNDS | AGTR1, AGTR2, REN | REN 3/4885 |
| US-20090253703-A1 | ORGANIC COMPOUNDS | AGTR1, AGTR2, REN | REN 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.